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Pulmonary Artery Embolotherapy in a
Patient with Type I Hepatopulmonary
Syndrome after Liver Transplantation
Although liver transplantation (LT) is the only effective treatment option for
hepatopulmonary syndrome (HPS), the post-LT morbidity and mortality have
been high for patients with severe HPS. We performed post-LT embolotherapy in
a 10-year-old boy who had severe type I HPS preoperatively, but he failed to
recover early from his hypoxemic symptoms after an LT. Multiple embolizations
were then successfully performed on the major branches that formed the abnor-
mal vascular structures. After the embolotherapy, the patient had symptomatic
improvement and he was discharged without complications.
epatopulmonary syndrome (HPS) is a pulmonary vascular disorder that is
characterized by the clinical triad of chronic liver disease, arteriovenous
shunts due to intrapulmonary vasodilatation, and arterial hypoxemia (1,
2). The pathophysiological mechanisms associated with HPS have not been identified.
Although HPS is most commonly found in patients with cirrhosis, it has also been seen
in patients with portal hypertension in the absence of cirrhosis, and HPS has also been
reported in the setting of acute and chronic hepatitis in the absence of portal hyperten-
sion (1, 3). The diagnosis of HPS is made by identifying the intrapulmonary shunts in
those patients with liver disease and hypoxemia. The shunts can be qualitatively
identified by performing contrast echocardiography and they can also be quantita-
tively measured by performing 99m-Tc macroaggregated albumin (MAA) lung
perfusion scanning (1-5).
There is currently no effective medical treatment for HPS. Liver transplantation (LT)
is considered as the only mainstay of therapy for HPS (1, 2). However, HPS may not
be reversible even after an LT in severe cases. A low preoperative partial pressure of
arterial oxygen (PaO2) and a large amount of shunting have been reported to be
associated with high post-LT morbidity and mortality (1).
We performed living donor LT in a patient with severe type I HPS (PaO2 = 39.7
mmHg). Although the liver function rapidly normalized, the patient’s hypoxemia and
dyspnea were not improved one month after the LT. Therefore, embolization of the
intrapulmonary shunts was attempted in an effort to reduce the amount of shunting.
The patient’s symptoms dramatically improved after the procedure.
CASE REPORT
The patient was a 10-year-old boy. A Kasai operation was performed for treating his
biliary atresia at three months after he was born. Although he had received
endoscopic ligation for grade III esophageal varices at the age of four because of
intermittent hematemesis and melena, he had maintained good general health and
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Hhepatic function for a long time after the Kasai operation.
However, he complained of dyspnea on exertion at eight
years of age. His symptoms continued for several months;
the patient was closely followed during this time to
determine the cause of the dyspnea. Saline contrast
echocardiography showed intrapulmonary right to left
shunts and so the diagnosis of HPS was made. The 99mTc-
MMA lung perfusion scanning showed 45% shunting, with
assuming that 13% of the cardiac output is delivered to the
brain (Fig. 1A). The arterial oxygen saturation (SaO2) at
the time of diagnosing HPS was 84% on the pulse
oximetry monitoring. The patient’s symptoms gradually
worsened. One year later, the PaO2 was as low as 37.3
mmHg and the SaO2 was only 71% in room air. The
patient’s activity was much decreased. An LT was
recommended for the serious symptoms associated with
the HPS, despite the relatively tolerable hepatic function.
The patient developed fever and a headache while
waiting for an LT. Two rim-enhanced cystic lesions in the
left frontal and parietal lobes were detected on the brain
computed tomography (CT) scan. Abscess removal via a
craniotomy was performed after 8-weeks of antibiotic
therapy. The infection was completely controlled, yet no
deceased donor graft was available for him. The patient’s
general activity continued to worsen; his physical activity
was markedly decreased. Thus, a living donor LT was
performed with the liver obtained from the patient’s
father. At the time of the LT, the hepatic function was
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Fig. 1. Embolotherapy for hepatopul-
monary syndrome in 10-year-old boy.
A. 99m-Tc macroaggregated albumin
lung perfusion scanning. Large propor-
tion of radioactive substance was
detected in extra-pulmonary areas;
mainly brain and kidneys. Amount of
intrapulmonary shunting was 45% with
assuming that 13% of cardiac output is
delivered to brain.
B. Pre-transplant pulmonary CT angiog-
raphy shows diffuse peripheral
pulmonary vasodilatation.
C. Pre-embolization angiography shows
abnormal tortuous and dilated vascular
structures in left upper lung field.
D. We performed embolization with 8
coils by selecting major branches that
formed abnormal vascular structures.
Right after embolization, we noted
marked decrease in size of abnormal
vascular structures and SaO2 had
increased by 10%. 
CDrelatively good compared to the patient’s general
condition. The serum total bilirubin and albumin levels
were 1.8 mg/dL and 3.4 g/dL, respectively. The interna-
tional normalized ratio (INR) for the prothrombin time was
1.35. The Child-Pugh score was 6 and the model for end-
stage liver disease (MELD) score was only 2. However, his
PaO2 and SaO2 were still very low in room air (39.7
mmHg and 73%, respectively). The CT angiography
showed diffuse peripheral pulmonary vasodilatation (Fig.
1B).
The LT was performed using an extended left liver graft
from the patient’s father. The graft included the middle
hepatic vein and the graft-to-recipient weight ratio
(GRWR) was 1.47. After the LT, the hepatic function
rapidly normalized by 10 days post surgery. However, the
respiratory symptoms did not improve even after one
month post surgery. The dyspnea was more severe than
that prior to the LT. The respiratory rate was 24 to 30 per
minute and the SaO2 was only 50 to 60% on the pulse
oximetry monitoring with facial mask O2 supplementation
of 8 L/min. The patient continued to have very limited
physical activity and he was bed-ridden.
Thirty days post surgery, the first embolization was
attempted in the left lung. The angiography showed
abnormal tortuous and dilated vascular structures in the
left upper lung field. Multiple embolizations were
performed on the major branches that formed the
abnormal vascular structures by using 8 MicroNester
�
Embolization Microcoils
TM 4 mm/14 cm (Cook,
Bloomington, IN) (Fig. 1E, F). Right after the first
embolization, the abnormal vascular structures were
markedly decreased and the SaO2 was increased by 10%.
The patient’s symptoms were slightly improved. The
respiratory rate decreased to 20 to 24 per minute and the
SaO2 increased to 65 to 75% on monitoring with facial
mask O2 supplementation of 5 L/min. The second
embolization was performed one week later in the right
lung. On the second angiography, the abnormal dilated
vascular structures were found mainly in the right lower
lung field. Multiple embolizations were performed with 9
coils in the same manner (Fig. 1E, F). After the
embolotherapy, the patient’s activity level gradually
improved and he was discharged, with O2 supplementation
of 5 L/min, three days after the second embolization.
Wheel-chair ambulation was possible for about ten
minutes without O2 at the time of discharge.
At three months post-LT, the patient was admitted with
seizures that were caused by an inactive brain lesion
related to the previous surgery. The seizures were treated
without complication. At that time, his PaO2 and SaO2
were 65 mmHg and 93%, respectively, on room air and
his activity had markedly improved; he played as actively
as the other children in his age group. The patient was
doing well with normal liver function at the two year
follow up. 
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Fig. 1. Embolotherapy for hepatopul-
monary syndrome in 10-year-old boy.
E. Pre-embolization angiography shows
abnormal dilated vascular structures
were mainly located in right lower lung
field.
F. We performed embolization with 9
coils. Patient was discharged three days
after second embolization with O2
supplementation of 5 L/min. 
EFDISCUSSION
Hepatopulmonary syndrome is defined by a widened
alveolar-arterial oxygen gradient (P[A-a]O2) that is the
result of intrapulmonary vasodilatation in the presence of
hepatic dysfunction or portal hypertension (5). The diagno-
sis of HPS can be variable based on the numeric threshold
that is used for hypoxemia (2). In general, the cases with
delayed positive-contrast echocardiography (the left atrial
microbubble opacification > 3 beats after the right atrial
opacification) as well as hypoxemia, with a PaO2 < 70
mmHg or P(A-a)O2 > 20 mmHg, are considered to have
HPS. HPS is found in 8 to 17% of the patients with cirrho-
sis (4, 6). The clinical features of HPS typically involve
respiratory complaints. Platypnea and orthodexia are
classically presented; they are highly specific signs for HPS
in the setting of liver cirrhosis, and they are the result of a
gravitational increase in blood flow through the dilated
vessels in the lung bases. Cough, clubbing and distal
cyanosis can also be associated with HPS (3).
In patients with the HPS, enhanced pulmonary produc-
tion of nitric oxide (NO) has been implicated in the
development of intrapulmonary vasodilatation (5). Acute
inhibition of NO production or its action with administer-
ing NG-nitro-L-arginine methyl ester (L-NAME) or
methylene blue, respectively, transiently improves HPS (2,
3, 5). However, all the medical treatments used to date
have been disappointing over the long-term (2, 3, 5). LT is
the only effective method for the total resolution or
marked improvement of HPS (5). Post-LT significant
improvement of gas exchange has been reported in more
than 80% of the patients with HPS (7). Yet the length of
time it takes for the hypoxemia to normalize after LT
varies and this may be more than one year (5). In addition,
the post-LT morbidity and mortality are increased in
patients with severe HPS, as compared to those who do
not have HPS and who have undergone LT (1, 5). For
patients with a low PaO2 less than 50 mmHg, the post-LT
survival has been reported to be lower than that for other
patients (5). Arguedas and colleagues (6) prospectively
evaluated the post-LT outcomes and predictive factors of
patients with HPS. According to their report, for the room
air PaO2 level, a threshold value of ≤ 50 mmHg had the
best predictive value for post-LT mortality with a sensitiv-
ity of 86% and a specificity of 82%; a threshold value of
≥ 20% for the MMA shunt fraction had the best predic-
tive value with a sensitivity of 100% and a specificity of
76%. The combination of the room air PaO2 ≤ 50 mmHg
and an MMA shunt fraction ≥ 20% further increased the
predictive value with a sensitivity of 86% and a specificity
of 88%. Among the patients who met these two criteria,
three fourths died after LT (a positive predictive value of
75%). Therefore, although LT is the best treatment
modality for HPS, LT should be performed with caution in
patients with severe HPS because of the high post-LT
mortality.
Embolotherapy is not an established therapy for the type
I HPS. The type II HPS with large pulmonary arteriove-
nous fistulas can be easily treated by embolizations (2, 8,
9). Some authors believe that coil embolization is the first
line of therapy for the type II HPS, followed by consider-
ing performance of LT (9). However, the type II HPS is not
a common type. Most patients with the HPS show type I,
which is characterized by diffuse precapillary pulmonary
artery dilatation without any definite arteriovenous
fistulas. Embolotherapy for the type I HPS is more difficult
and it is still unreliable as an effective treatment method.
There are limited case reports of embolizations for type I
HPS. Ryu and Oh (10) first reported successful diffuse
embolization as a rescue therapy for a patient with the
type I HPS and who was waiting for an LT. They selected
the main branches forming the abnormal tortuous vascular
structures and they performed multiple embolizations at
the level of the segmental arteries. They reported that the
patient had symptomatic improvement and he maintained
his respiration with O2 supplementation of 1 L/min,
although the long-term outcome is unknown. Saad et al.
(9) also reported successful post-LT pulmonary arteriolar
embolizations for the type I HPS, which were performed
to reduce the morbidity during the postoperative period.
However, there is little accumulated experience with
embolotherapy for the type I HPS. Thus, its efficacy and
risks have not yet been established.
The patient reported on here had severe HPS preopera-
tively. The laboratory hepatic function was completely
normal by 10 days after the surgery. However, sympto-
matic improvement was not achieved at one month post-
LT, and the patient’s general physical activity further
deteriorated. Delayed improvement of hypoxemia has
been previously reported (5), and the post-LT mortality
has been reported to be very high for such patients (1, 6).
Moreover, the long duration of inactivity could led to
other complications such as pneumonia and bedsores.
Despite that our patient had the type I HPS, multiple
embolizations were successfully performed on the major
arterioles forming the abnormal tortuous and dilated
vascular structures. The patient could be discharged with
improved symptoms after embolotherapy and two months
later there was nearly normal arterial oxygenation and
active movement when breathing room air. Therefore,
post-transplant embolotherapy for the type I HPS might be
effective and safe in patients who have severe HPS
Lee et al.
488 Korean J Radiol 11(4), Jul/Aug 2010preoperatively and who fail to recover early from their
hypoxemic symptoms. Although this treatment modality
cannot completely resolve the type I HPS, it can accelerate
the post-LT recovery and decrease the risk of postopera-
tive morbidity and mortality by reducing the amount of
shunting. 
In conclusion, although LT is the only established
effective therapy for HPS that can totally resolve or
markedly improve HPS, the patients with severe HPS may
have sustained hypoxemic symptoms for a long time after
an LT; such patients have a high risk of postoperative
morbidity and mortality. We found that embolotherapy
could improve the symptoms by reducing the amount of
shunting even in a case with the type I HPS. Therefore,
post-transplant pulmonary artery embolization might be a
useful treatment option to accelerate the post-LT recovery
and to decrease the risk of morbidity and mortality in
patients who fail to recover early after an LT. Further
study is needed to confirm these findings. 
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